Dynacure secures rights to Ionis rare disease drug

A collaboration between the companies takes a step forward, with the French biotech licensing one of Ionis' early-stage antisense candidates.

By Suzanne Elvidge • Nov. 10, 2017

Prescribed Reading: Buyer's remorse for biopharma

Most of the major deal developments of late have been companies handing back the rights to assets they previously licensed as they try to right-size portfolios. 

By Lisa LaMotta • Nov. 10, 2017

Sanofi picks up BTK inhibitor for MS development

After ending its fruitful deal with Regeneron, Sanofi acquires a new asset to add to its roster of potential blockbusters. 

By Lisa LaMotta • Nov. 9, 2017

Takeda pursuing needle-free delivery for its top-selling biologic

Linking up with Portal Instruments, the pharma is developing a device that uses pressurized liquid to administer biologics and plans to test it first with Entyvio.

By Jacob Bell • Nov. 8, 2017

Dermira drops UCB drug to fund other launches

Returning Cimzia rights gets Dermira $11 million in 2017 and $39 million in 2018 that could help fund its late-stage portfolio. 

By Suzanne Elvidge • Nov. 7, 2017

Valeant hands Sprout back to former owners

Despite paying $1 billion to buy the company two years ago, Valeant never found success in selling Sprout's female libido drug Addyi.

By Jacob Bell • Nov. 6, 2017

Mallinckrodt continues pipeline revamp with Ocera buy

The deal gives Mallinckrodt access to hepatic encephalopathy drug OCR-002, which the company believes can make a turn around in the clinic.

By Jacob Bell • Nov. 3, 2017

Prescribed Reading: Cancer market facing several shake-ups

Merck pulled a Keytruda application in Europe, and AstraZeneca got a key approval for Calquence — decisions that could have dramatic impacts on different areas of the oncology space. 

By Lisa LaMotta • Nov. 3, 2017

Boehringer's NASH dash gets a boost from Dicerna

The German drugmaker and the Massachusetts biotech have entered a research and licensing deal focused on RNAi therapies for the prominent liver disease.

By Jacob Bell • Nov. 2, 2017

Pfizer ready for a fight as biosimilar sales continue to lag

The big pharma is taking on rival J&J in an effort to gain market share for its biosimilar of blockbuster RA drug Remicade.

By Lisa LaMotta • Oct. 31, 2017

Sumitomo Dainippon Pharma and Poxel strike $300M Asian deal

Poxel's shares spiked up on a deal that will give the European biopharma a foothold in Asian markets. 

By Suzanne Elvidge • Oct. 31, 2017

AstraZeneca hands Mereo rights to lung drug

In yet another sale, the big drugmaker is giving up an exclusive license to AZD9668 that includes an option to acquire.

By Jacob Bell • Oct. 30, 2017

Novartis bolsters oncology with $3.9B Advanced Accelerator buy

Advanced Accelerator, a specialist in so-called radiopharmaceuticals, recently won EU approval for a treatment of neuroendocrine tumors. 

By Ned Pagliarulo • Oct. 30, 2017

Prescribed Reading: Disappointing quarters all around

With some exceptions, third quarter reports so far have largely been a letdown for the sector, lowering expectations as investors turn toward 2018. 

By Lisa LaMotta • Oct. 27, 2017

CVS reportedly in talks to buy Aetna

The Wall Street Journal reported a $66 billion deal is being discussed as CVS looks to bolster itself in preparation for Amazon's potential entry into the drug distribution business.

By Shannon Muchmore • Oct. 27, 2017

Neos stock shoots up after PDL makes all-cash offer public

After several attempts to quietly acquire Neos, PDL is taking its offer hostile in hopes of swaying shareholders. 

By Suzanne Elvidge • Oct. 27, 2017

Incyte pays $150M to bolster combo strategy

Through a deal with MacroGenics, Incyte is adding a second checkpoint inhibitor to its pipeline to test in combination with its slate of immunotherapies.

By Lisa LaMotta • Oct. 25, 2017

AbbVie taps Alector for deeper dive into Alzheimer's

As research into the immune system booms, the two companies will investigate treatments that aim to use the body's defenses to fight neurodegenerative disorders.

By Jacob Bell • Oct. 25, 2017

Reader poll: Pfizer most likely buyer for Spark

When asked what company would be most interested in the gene therapy drugmaker, BioPharma Dive readers had mixed feelings, but Pfizer won out. 

By Lisa LaMotta • Oct. 25, 2017

Biogen doubling down on aducanumab

The big biotech is paying $150 million to reclaim 15% of the Alzheimer's candidate's potential royalties, and may take the agreement one step further.

By Jacob Bell • Oct. 24, 2017

Finch, Crestovo merger pushes forward C diff therapeutic

The combination of two microbiota-based companies could help make microbe-based treatments mainstream.

By Suzanne Elvidge • Oct. 24, 2017

Eisai shows confidence in Biogen's Alzheimer's drug

The Japanese pharma expanded its deal with the big biotech around the closely-watched Alzheimer's disease drug aducanumab. 

By Lisa LaMotta • Oct. 23, 2017

Prescribed Reading: Blockbuster potential thwarted; generics consolidate

The past week saw multiple companies discontinue development of potential blockbusters, while a tightening generics market prompted a new merger.

By Lisa LaMotta • Oct. 20, 2017

What's next for biopharma Q3 earnings

Bristol-Myers, AbbVie, Merck, Gilead and several other notable names will all host third quarter earnings calls this week.

By Ned Pagliarulo , Lisa LaMotta , Jacob Bell • Oct. 20, 2017

Arcturus expands partnership with J&J into hepatitis B

On the verge of going public through a reverse merger, Arcturus locks down its second partnership with the big pharma. 

By Suzanne Elvidge • Oct. 20, 2017